01/31/2017
https://www.congress.gov...
"I don't think that much of what labor is advocating for is considered extreme today."
"I think we have learned a lot of lessons over the past decade about the difference between unilateral action and multilateral action."
"None of the reasons that the FDA cites are due to pricing issues, and certainly none of them are related to 340(b)."
"According to probably the most comprehensive FDA study that we have, the leading cause of these drug shortages are quality problems during manufacturing."